Intravitreal tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, partially suppresses and regresses laser-induced choroidal neovascularization in a rat model

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 10, 2014, Pages 847-853

  Kim, Jaeryung ^a   Kim, Tae Eun ^b   Kim, Ju A ^b   Yun, Ji Hyun ^b   Sohn, Seongsoo ^c   Shim, Sang Ryeol ^d   Lee, Sang Hoon ^e   Kim, Sang Jin ^b,c  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d PharmAbcine   (South Korea)

^e Hanwha Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; HUMAN MONOCLONAL ANTIBODY; ISOLECTIN B4; ISOTHIOCYANIC ACID DERIVATIVE; PHOSPHATE BUFFERED SALINE; TANIBIRUMAB; TETRAMETHYLRHODAMINE ISOTHIOCYANATE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; GRIFFONIA SIMPLICIFOLIA LECTINS; MONOCLONAL ANTIBODY; PLANT LECTIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BROWN NORWAY RAT; CHEMICAL LABELING; CHOROID; CONTROLLED STUDY; FEASIBILITY STUDY; IMAGE ANALYSIS; LASER COAGULATION; NONHUMAN; PIGMENT EPITHELIUM; RAT; SCLERA; SUBRETINAL NEOVASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHOROIDAL NEOVASCULARIZATION; DISEASE MODEL; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; RANDOMIZATION; STAINING;

ANIMALS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; PLANT LECTINS; RANDOM ALLOCATION; RATS; STAINING AND LABELING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84915775917     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0021     Document Type: Article

References (32)

1. Lim, L.S., Mitchell, P., Seddon, J.M., et al. Age-related macular degeneration. Lancet. 379:1728-1738, 2012.
2. Jager, R.D., Mieler, W.F., and Miller, J.W. Age-related macular degeneration. N. Engl. J. Med. 358:2606-2617, 2008.
3. Wong, T.Y., Chakravarthy, U., Klein, R., et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 115:116-126, 2008.
4. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:27-31, 1995.
5. Carmeliet, P., Ferreira, V., Breier, G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:435-439, 1996.
6. Shibuya, M., Ito, N., and Claesson-Welsh, L. Structure and function of VEGF receptor-1 and-2. Curr. Topics Micro-biol. Immunol. 237:59-83, 1999.
7. Takahashi, T., Yamaguchi, S., Chida, K., et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 20:2768-2778, 2001.
8. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., et al. Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:26988-26995, 1994.
9. Takeda, A., Hata, Y., Shiose, S., et al. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch. Clin. Exp. Ophthalmol. 241:765-772, 2003.
10. Kami, J., Muranaka, K., Yanagi, Y., et al. Inhibition of choroidal neovascularization by blocking vascular endo-thelial growth factor receptor tyrosine kinase. Jpn. J. Ophthalmol. 52:91-98, 2008.
11. Otani, A., Takagi, H., Oh, H., et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc. Res. 64:162-169, 2002.
12. Lashkari, K., et al. Association for research in vision & ophthalmology. Invest. Ophthalmol. Vis. Sci. 54:E-Abstract 4999, 2013.
13. Lee, S.H. Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch. Pharm. Res. 34:1223-1226, 2011.
14. Kim, S.J., Kim, J., Lee, J., et al. Intravitreal human complement factor H in a rat model of laser-induced choroidal neovascularisation. Br. J. Ophthalmol. 97:367-370, 2013.
15. Edelman, J.L., and Castro, M.R. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp. Eye Res. 71:523-533, 2000.
16. Lambert, V., Munaut, C., Noël, A., et al. Influence of plasminogen activator inhibitor type 1 on choroidal neo-vascularization. FASEB J. 15:1021-1027, 2001.
17. Presta, L.G., Chen, H., O'Connor, S.J., et al. Humanisation of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:4593-4599, 1997.
18. Lowe, J., Araujo, J., Yang, J., et al. Ranibizumab inhibits multiple forms of biologically active VEGF in vitro and in vivo. Exp. Eye Res. 85:425-430, 2007.
19. Honda, M., Asai, T., Umemoto, T., et al. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. Arch. Ophthalmol. 129:317-321, 2011.
20. Kang, S., Roh, C.R., Cho, W.K., et al. Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice. Curr. Eye Res. 38:119-127, 2013.
21. Huang, H., Shen, J., and Vinores, S.A. Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. PLoS One. 6:e21411, 2011.
22. Ho, M., Royston, I., and Beck, A. 2nd PEGS Annual Symposium on Antibodies for Cancer Therapy. MAbs. 4: 562-570, 2012.
23. Van de Veire, S., Stalmans, I., Heindryckx, F., et al. Further pharmacological and genetic evidence for the efficacyofPlGF inhibition in cancer and eye disease. Cell. 141:178-190, 2010.
24. Huang, H., Parlier, R., Shen, J.K., et al. VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PLoS One. 8:e71808, 2013.
25. D'Amato, R., Wesolowski, E., and Smith, L.E. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein labeled dextrans in the mouse. Microvasc. Res. 46:135-142, 1993.
26. Semkova, I., Peters, S., Welsandt, G., et al. Investigation of laser-induced choroidal neovascularization in the rat. Invest. Ophthalmol. Vis. Sci. 44:5349-5354, 2003.
27. Apte, R.S., Barreiro, R.A., Duh, E., et al. Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest. Ophthalmol. Vis. Sci. 45:4491-4497, 2004.
28. Campos, M., Amaral, J., Becerra, S.P., et al. A novel imaging technique for experimental choroidal neovascular-ization. Invest. Ophthalmol. Vis. Sci. 47:5163-5170, 2006.
29. Lu, F., and Adelman, R.A. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch. Clin. Exp. Ophthalmol. 247:171-177, 2009.
30. Yu, L., Wu, X., Cheng, Z., et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest. Ophthalmol. Vis. Sci. 49:522-527, 2008.
31. Beazley-Long, N., Hua, J., Jehle, T., et al. VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. Am. J. Pathol. 183:918-929, 2013.
32. Tokunaga, C.C., Mitton, K.P., Dailey, W., et al. Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Invest. Oph-thalmol. Vis. Sci. 28:1884-1892, 2014.